×
About 219 results

ALLMedicine™ Schnitzler Syndrome Center

Research & Reviews  109 results

Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677784
Arthritis Research & Therapy; Darrieutort-Laffite C, Ansquer C et. al.

Nov 19th, 2020 - To report on the characteristics and long-term course of rheumatic manifestations in Schnitzler syndrome (SchS). A retrospective cohort study of patients with SchS followed between 2000 and 2020. Inclusion criteria included a diagnosis of SchS (St...

A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-...
https://doi.org/10.1007/s10067-020-05204-2
Clinical Rheumatology; Yan R, Cao W et. al.

Jun 8th, 2020 - Schnitzler syndrome (SchS) is a rare acquired systemic autoinflammatory disease. The major clinical features of SchS are urticarial rash and monoclonal gammopathy, accompanied by fever, joint pain, and lymphadenopathy. There were few reports about...

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic liter...
https://doi.org/10.1016/j.semarthrit.2020.05.002
Seminars in Arthritis and Rheumatism; Betrains A, Staels F et. al.

Jun 5th, 2020 - Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis. Canakinumab is a fully human monoclonal anti-i...

Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081793
Clinical Medicine (London, England); Zampeli E, Marinos L et. al.

Mar 19th, 2020 - Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.|2020|Zampeli E,Marinos L,Karakatsanis SJ,|

Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.
https://doi.org/10.1016/j.jaci.2019.12.909
The Journal of Allergy and Clinical Immunology; Krause K, Bonnekoh H et. al.

Jan 15th, 2020 - Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.|2020|Krause K,Bonnekoh H,Ellrich A,Tsianakas A,Wagner N,|

see more →

Clinicaltrials.gov  109 results

Rheumatic involvement and bone scan features in Schnitzler syndrome: initial and follow...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677784
Arthritis Research & Therapy; Darrieutort-Laffite C, Ansquer C et. al.

Nov 19th, 2020 - To report on the characteristics and long-term course of rheumatic manifestations in Schnitzler syndrome (SchS). A retrospective cohort study of patients with SchS followed between 2000 and 2020. Inclusion criteria included a diagnosis of SchS (St...

A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-...
https://doi.org/10.1007/s10067-020-05204-2
Clinical Rheumatology; Yan R, Cao W et. al.

Jun 8th, 2020 - Schnitzler syndrome (SchS) is a rare acquired systemic autoinflammatory disease. The major clinical features of SchS are urticarial rash and monoclonal gammopathy, accompanied by fever, joint pain, and lymphadenopathy. There were few reports about...

Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic liter...
https://doi.org/10.1016/j.semarthrit.2020.05.002
Seminars in Arthritis and Rheumatism; Betrains A, Staels F et. al.

Jun 5th, 2020 - Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis. Canakinumab is a fully human monoclonal anti-i...

Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081793
Clinical Medicine (London, England); Zampeli E, Marinos L et. al.

Mar 19th, 2020 - Images of the month 1: Schnitzler syndrome: an acquired autoinflammatory syndrome.|2020|Zampeli E,Marinos L,Karakatsanis SJ,|

Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.
https://doi.org/10.1016/j.jaci.2019.12.909
The Journal of Allergy and Clinical Immunology; Krause K, Bonnekoh H et. al.

Jan 15th, 2020 - Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.|2020|Krause K,Bonnekoh H,Ellrich A,Tsianakas A,Wagner N,|

see more →

News  1 results

Successful Treatment of Schnitzler Syndrome With Canakinumab
https://www.mdedge.com/dermatology/article/86939/urticaria/successful-treatment-schnitzler-syndrome-canakinumab
Robbie Pesek, MD, Roger Fox, MD

Sep 3rd, 2014 - To the Editor: Schnitzler syndrome occurs with a triad of chronic urticaria, recurring fevers, and monoclonal gammopathy. It was recognized as a clinical entity in 1972; now nearly 200 patients are reported in the medical literature.

see more →